Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Disease Burden Subgroup Analysis of Health-Related Quality of Life of Blinatumomab Versus Standard-of-Care Chemotherapy in Patients with Relapsed or Refractory Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic Leukemia in a Randomized, Open-Label Phase 3 Study (TOWER)

Anthony S. Stein, MD, Zachary F. Zimmerman, Paul Cannell, Hervé Dombret, Johan Maertens, MD, Max S. Topp, Janet L. Franklin, Ze Cong, PhD MS, Xinke Zhang, Yan Li, Andre Schuh

Blood (2018) 132 (Supplement 1): 3967.

https://doi.org/10.1182/blood-2018-99-115160

Published: 2018

Journal Articles

Age Subgroup Analysis of Health-Related Quality of Life of Blinatumomab Versus Standard-of-Care Chemotherapy in Patients with Relapsed or Refractory Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic Leukemia in a Randomized, Open-Label, Phase 3 Study (TOWER)

Max S. Topp, Zachary F. Zimmerman, Paul Cannell, Hervé Dombret, Johan Maertens, MD, Anthony S. Stein, MD, Janet L. Franklin, Ze Cong, PhD MS, Xinke Zhang, Andre Schuh

Blood (2018) 132 (Supplement 1): 5165.

https://doi.org/10.1182/blood-2018-99-115123

Published: 2018

Journal Articles

A Systematic Literature Review (SLR) of Clinical Outcomes after Stem Cell Transplantation (SCT) in Adult Acute Lymphoblastic Leukemia (ALL) Patients with or without Minimal Residual Disease (MRD)

Monica Turner, Shweta Shah, Amber Martin, Ze Cong, PhD MS, Anthony S. Stein, MD

Blood (2018) 132 (Supplement 1): 5292.

https://doi.org/10.1182/blood-2018-99-112981

Published: 2018

Journal Articles

Clinicians' Perspectives on Cure in Adult Acute Lymphoblastic Leukemia (ALL) Patients with Minimal Residual Disease (MRD) - Findings from a UK Delphi Panel

David Marks, Wendy Gidman, PhD MSc, BPharm, Heather M Wieffer, PhD, Lirong Zhang, MSc, Ze Cong, PhD MS, Shweta Shah

Blood (2018) 132 (Supplement 1): 5865.

https://doi.org/10.1182/blood-2018-99-118029

Published: 2018

Journal Articles

Healthcare Resource Utilization in Adult Patients with B-Cell Precursor Acute Lymphoblastic Leukemia in First Hematologic Complete Remission with and without Minimal Residual Disease

Darya Rose, Shweta Shah, Nicholas Despiegel, Shruti Tibrewala, MBA, MPH, Anita Chawla, Ze Cong, PhD MS

Blood (2018) 132 (Supplement 1): 4732.

https://doi.org/10.1182/blood-2018-99-111360

Published: 2018

Journal Articles

Cost-Effectiveness of Blinatumomab Versus Standard of Care in Adult Patients with Philadelphia-Chromosome-Negative B-Precursor Acute Lymphoblastic Leukemia in First Hematological Complete Remission (CR) with Minimal Residual Disease (MRD) from a US Payer Perspective

Thomas Delea, MBA, MSIA, Nicholas Despiegel, Diana Boyko, Jordan Amdahl, Ze Cong, PhD MS, Jerald Radich, MD

Blood (2018) 132 (Supplement 1): 4746.

https://doi.org/10.1182/blood-2018-99-115230

Published: 2018

NARROW

Disease Burden Subgroup Analysis of Health-Related Quality of Life of Blinatumomab Versus Standard-of-Care Chemotherapy in Patients with Relapsed or Refractory Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic Leukemia in a Randomized, Open-Label Phase 3 Study (TOWER)

Age Subgroup Analysis of Health-Related Quality of Life of Blinatumomab Versus Standard-of-Care Chemotherapy in Patients with Relapsed or Refractory Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic Leukemia in a Randomized, Open-Label, Phase 3 Study (TOWER)

A Systematic Literature Review (SLR) of Clinical Outcomes after Stem Cell Transplantation (SCT) in Adult Acute Lymphoblastic Leukemia (ALL) Patients with or without Minimal Residual Disease (MRD)

Clinicians' Perspectives on Cure in Adult Acute Lymphoblastic Leukemia (ALL) Patients with Minimal Residual Disease (MRD) - Findings from a UK Delphi Panel

Healthcare Resource Utilization in Adult Patients with B-Cell Precursor Acute Lymphoblastic Leukemia in First Hematologic Complete Remission with and without Minimal Residual Disease

Cost-Effectiveness of Blinatumomab Versus Standard of Care in Adult Patients with Philadelphia-Chromosome-Negative B-Precursor Acute Lymphoblastic Leukemia in First Hematological Complete Remission (CR) with Minimal Residual Disease (MRD) from a US Payer Perspective

Email alerts

ASH Publications

American Society of Hematology

Disease Burden Subgroup Analysis of Health-Related Quality of Life of Blinatumomab Versus Standard-of-Care Chemotherapy in Patients with Relapsed or Refractory Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic Leukemia in a Randomized, Open-Label Phase 3 Study (TOWER)

Age Subgroup Analysis of Health-Related Quality of Life of Blinatumomab Versus Standard-of-Care Chemotherapy in Patients with Relapsed or Refractory Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic Leukemia in a Randomized, Open-Label, Phase 3 Study (TOWER)

A Systematic Literature Review (SLR) of Clinical Outcomes after Stem Cell Transplantation (SCT) in Adult Acute Lymphoblastic Leukemia (ALL) Patients with or without Minimal Residual Disease (MRD)

Clinicians' Perspectives on Cure in Adult Acute Lymphoblastic Leukemia (ALL) Patients with Minimal Residual Disease (MRD) - Findings from a UK Delphi Panel

Healthcare Resource Utilization in Adult Patients with B-Cell Precursor Acute Lymphoblastic Leukemia in First Hematologic Complete Remission with and without Minimal Residual Disease

Cost-Effectiveness of Blinatumomab Versus Standard of Care in Adult Patients with Philadelphia-Chromosome-Negative B-Precursor Acute Lymphoblastic Leukemia in First Hematological Complete Remission (CR) with Minimal Residual Disease (MRD) from a US Payer Perspective

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only